Turnstone Biologics Corp. (TSBX)

NASDAQ: TSBX · IEX Real-Time Price · USD

3.050

+0.180 (6.27%)

At close: May 10, 2024, 4:00 PM

3.120

+0.070 (2.30%)

After-hours: May 10, 2024, 7:47 PM EDT

Turnstone Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	19.31	73.3	101.29
Revenue Growth (YoY)	-73.66%	-27.64%	-
Gross Profit	19.31	73.3	101.29
Selling, General & Admin	17.85	18.22	13.55
Research & Development	60.49	86.7	54.75
Operating Expenses	78.34	104.93	68.3
Operating Income	-59.03	-31.63	32.99
Other Expense / Income	-3.55	-0.93	-0.71
Pretax Income	-55.49	-30.69	33.7
Income Tax	-0.29	0.14	0.43
Net Income	-55.2	-30.83	33.27
Preferred Dividends	0.04	0.19	29.79
Net Income Common	-55.24	-31.02	3.48
Shares Outstanding (Basic)	12	2	17
Shares Outstanding (Diluted)	12	2	22
Shares Change	365.39%	-88.48%	-
EPS (Basic)	-4.78	-12.49	0.20
EPS (Diluted)	-4.78	-12.49	0.16
Free Cash Flow	-66.95	-76.23	-49.04
Free Cash Flow Per Share	-5.79	-30.68	-2.86
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-305.77%	-43.15%	32.57%
Profit Margin	-286.12%	-42.32%	3.43%
Free Cash Flow Margin	-346.78%	-104.00%	-48.41%
Effective Tax Rate	-	-	1.28%
EBITDA	-52.69	-26.79	35.71
EBITDA Margin	-272.91%	-36.55%	35.26%
Depreciation & Amortization	2.8	3.9	2.01
EBIT	-55.49	-30.69	33.7
EBIT Margin	-287.40%	-41.87%	33.27%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).